PT  - JOURNAL ARTICLE
AU  - rao, Ramya S
AU  - Moadel, Renee
AU  - chun, kwang
AU  - Freeman, Leonard
AU  - Gartrell, Benjamin
TI  - <strong>Bone scan response to newer therapies in castration resistant prostate cancer.</strong>
DP  - 2015 May 01
TA  - Journal of Nuclear Medicine
PG  - 1453--1453
VI  - 56
IP  - supplement 3
4099  - http://jnm.snmjournals.org/content/56/supplement_3/1453.short
4100  - http://jnm.snmjournals.org/content/56/supplement_3/1453.full
SO  - J Nucl Med2015 May 01; 56
AB  - 1453 Objectives Since 2011 several novel therapeutic agents have been introduced for treatment of metastatic castration resistant prostate cancer (mCRPC). These include the chemotherapeutic agent cabazitaxel, hormonal agents Abiraterone and Ezalutamide, the vaccine Sipuleucel-T and the radionuclide, radium-223 chloride. Aim of the study was to do a retrospective analysis of patients on newer therapies and compare response to therapy with respect to bone scan, prostate specific antigen (PSA) and alkaline phosphatase (Alp) levels after 8 weeks and within 6 months of initiation of therapy and follow up response after 6 months of therapy.Methods We retrospectively analyzed data of patients diagnosed with mCRPC over the past 2 years and on newer therapies.Correlated baseline bonescan with bonescan between 2 to 6 months following iniation of therapy and after 6 months of therapy. Bone scan findings were defined as stable, improvement or worsening of the disease. We obtained PSA and Alp levels at +/_ 15 days of bone scan.Results Of the 48 mCRPC patients, 23 patients received Abiraterone,11 received Enzalutamide, 5 patients each cabazitaxel and Sipuleucel-T. Due to progressive disease 4 patients received Ra-223 therapy. All patients on Sipuleucel-T and cabazitaxel showed disease progression with respect to bone scan, PSA and Alp levels. 6 patients on Abiraterone showed improvement /stable disease and 12 patients showed worsening while two patients on Enzalutamide showed improvement and 2 showed worsening. Bone scan findings correlated with PSA and Alp levels. Bone scan was not available on 5 patients each on Enzalutamide and Abiraterone. Bone scan was available on 3 patients who received Ra-223 therapy and all of them showed improvement.Conclusions Patients on Abiraterone and Enzalutamide are most likely to have improvement on bonescan. Ra 223 therapy was also associated with favourable bonescan response. Improvement in bonescan to these therapies correlated with decrease in PSA and alkaline phosphatase levels.